全文获取类型
收费全文 | 6165篇 |
免费 | 293篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 123篇 |
妇产科学 | 58篇 |
基础医学 | 1163篇 |
口腔科学 | 146篇 |
临床医学 | 356篇 |
内科学 | 1270篇 |
皮肤病学 | 178篇 |
神经病学 | 581篇 |
特种医学 | 272篇 |
外科学 | 947篇 |
综合类 | 18篇 |
预防医学 | 152篇 |
眼科学 | 149篇 |
药学 | 451篇 |
中国医学 | 12篇 |
肿瘤学 | 607篇 |
出版年
2023年 | 34篇 |
2022年 | 56篇 |
2021年 | 106篇 |
2020年 | 53篇 |
2019年 | 99篇 |
2018年 | 90篇 |
2017年 | 86篇 |
2016年 | 108篇 |
2015年 | 102篇 |
2014年 | 147篇 |
2013年 | 180篇 |
2012年 | 259篇 |
2011年 | 310篇 |
2010年 | 148篇 |
2009年 | 148篇 |
2008年 | 293篇 |
2007年 | 308篇 |
2006年 | 336篇 |
2005年 | 384篇 |
2004年 | 374篇 |
2003年 | 380篇 |
2002年 | 371篇 |
2001年 | 149篇 |
2000年 | 148篇 |
1999年 | 147篇 |
1998年 | 102篇 |
1997年 | 110篇 |
1996年 | 82篇 |
1995年 | 77篇 |
1994年 | 70篇 |
1993年 | 67篇 |
1992年 | 129篇 |
1991年 | 94篇 |
1990年 | 87篇 |
1989年 | 102篇 |
1988年 | 78篇 |
1987年 | 80篇 |
1986年 | 89篇 |
1985年 | 66篇 |
1984年 | 52篇 |
1983年 | 33篇 |
1980年 | 31篇 |
1979年 | 26篇 |
1978年 | 38篇 |
1977年 | 23篇 |
1976年 | 27篇 |
1975年 | 18篇 |
1973年 | 23篇 |
1972年 | 19篇 |
1970年 | 18篇 |
排序方式: 共有6499条查询结果,搜索用时 15 毫秒
91.
A Double-Blind Controlled Study of Clinical Efficacy of Maprotiline and Amitriptyline in Depression 总被引:1,自引:0,他引:1
Shosuke Watanabe M.D. Shigeo Yokoyama M.D. Shinsuke Kubo M.D. Hiroyuki Iwai M.D. Chie Kuyama M.D. 《Psychiatry and clinical neurosciences》1978,32(1):1-31
A multiclinic double-blind controlled study was performed on the effects of MAP in both inpatients and outpatients with AMT as control drug.
- 1 Subjects consisted of 41 male and 45 female patients suffering from various types of depression. MAP was assigned to 42 cases and AMT to 44 cases. Of these patients, 14 MAP cases and 10 AMT cases were subsequently dropped for a variety of reasons to obtain 28 MAP cases and 34 AMT cases as evaluable.
- 2 The global improvement ratings were compared and found not significantly different for any week between the two treatments.
- 3 The global improvement ratings by the characteristic features of patients did not show any significant difference in any items studied between the two treatments.
- 4 The symptomatic improvement ratings (on the Hamilton R.S. for assessment by the physician) indicated that AMT was more effective on “anxiety (psychic).”
- 5 The symptomatic improvement ratings (on the Beck self-assessment scale by the patient) indicated that MAP was more effective on “work” and AMT on “pathos”, “feeling of satisfaction”, “withdrawal” and “loss of libido.”
- 6 During the treatment period, 74.3 percent of the MAP group and 76.9 percent of the AMT group of patients showed some side effects or accompanying symptoms, with no significant difference recognized between the two treatments. Itemwise, however, the incidence of tremor was significantly lower (p-=0.06) in the MAP group. Moreover, the MAP group tended to be less liable to such anti-cholinergic side effects as dry mouth, constipation, trouble of accommodation, urinary disturbance and palpitation.
- 7 On the basis of the above findings, it is concluded that MAP is as effective against depression as AMT and less liable to the anticholinergic side effects. It is, therefore, a very useful antidepressant.
92.
Does Hyperthermia Induce Peritoneal Damage in Continuous Hyperthermic Peritoneal Perfusion? 总被引:3,自引:0,他引:3
Shido A Ohmura S Yamamoto K Kobayashi T Fujimura T Yonemura Y 《World journal of surgery》2000,24(5):507-511
To investigate the mechanisms of the peritoneal damage induced by continuous hyperthermic peritoneal perfusion (CHPP), protein
and fluid loss during and after CHPP and continuous normothermic peritoneal perfusion (CNPP) was studied. Sixteen patients
with advanced gastric cancer underwent peritoneal perfusion therapy with saline solution containing 150 to 300 mg cisplatin
and 30 to 60 mg mitomycin C for 60 minutes. The temperature in Douglas' pouch was maintained at 42.0°C in the CHPP group (n= 9) and 37.0°C in the CNPP group (n= 7) during perfusion. No statistical differences were found in patients' characteristics between the groups except the maximum
temperature in Douglas' pouch during perfusion (41.6°± 0.4°C and 37.6°± 0.4°C in CHPP and CNPP groups, respectively, p < 0.05). The amount of protein lost into the perfusate was 0.35 ± 0.22 g/kg body weight in the CHPP group and 0.37 ± 0.19
g/kg in the CNPP group, showing no significant difference. On the day of surgery, there was no significant difference in the
amount of protein and fluid lost through the abdominal drains between the CHPP group (27.9 ± 24.6 mg/kg/hr and 0.94 ± 0.63
ml/kg/hr, respectively) and the CNPP group (25.9 ± 8.6 mg/kg/hr and 1.03 ± 0.31 ml/kg/hr, respectively). We could not find
any significant differences in postoperative protein and fluid loss between the groups on the following 3 days either. We
conclude that the peritoneal damage by CHPP is not caused by the hyperthermia but by the peritoneal perfusion with saline
solution containing anticancer drugs. 相似文献
93.
The expression of alternatively spliced mRNAs for amyloid precursor protein (APP) isoforms and their translation products were examined in the rat cerebral cortex 1, 3, 6, and 12 h and 1, 3, and 7 days (n = 4-5 in each group) after fluid-percussion brain injury. In situ hybridization studies demonstrated that the expression of APP695 mRNA decreased in and around the damaged area of the cerebral cortex exposed to fluid-percussion injury 1 h after the insult. On the other hand, APP751/770 mRNAs were increased in the regions surrounding the damaged cortical areas 1 day after the injury. An increase of immunoreactive APP was detected in the regions around the damaged cortical areas 3 h after traumatic injury and maintained for the following 3 days. The APP immunoreactivity in the damaged cortices declined to the level of sham-operated animals by post-experimental day 7. Using an anti-amyloid beta (Abeta) protein (17-24) antibody, no deposits of immunoreactive Abeta (17-24) were observed in any of the samples examined in these experiments. These results suggest that the induction of Kunitz-type protease inhibitor (KPI) domain-containing APP mRNAs and the increased accumulation of APP are involved in the physiological and neuropathological responses of brains under various neurodegenerative conditions, including head trauma. 相似文献
94.
A case of inclusion body myositis with benign monoclonal gammopathy successfully responding to repeated immunoabsorption 总被引:3,自引:0,他引:3 下载免费PDF全文
Nakayama T Horiuchi E Watanabe T Murayama S Nakase H 《Journal of neurology, neurosurgery, and psychiatry》2000,68(2):230-233
A 69 year old woman with inclusion body myositis is described. She presented with benign monoclonal gammopathy. She was resistant to steroid therapy, but responded to repeated immunoabsorption. Up to now, there has been no established therapy for inclusion body myositis, including IVIg. It is suggested that immunoabsorption could be an alternative therapy for inclusion body myositis, when it was accompanied by immunological abnormality. 相似文献
95.
96.
Yumiko Kasugai Hiroyuki Tagawa Yoshihiro Kameoka Yasuo Morishima Shigeo Nakamura Masao Seto 《Clinical cancer research》2005,11(23):8265-8272
PURPOSE: Increases in gene dosage through DNA amplification represents a common feature of many tumors and can result in the up-regulation of tumor-promoting genes. Our recent genome-wide, array-based comparative genomic hybridization analysis of 66 cases of diffuse large B-cell lymphoma found that genomic gain of 6p21 was observed in as many as 17 cases, including 14 cases with low-level copy number gain and three cases with high-level copy number gains (amplifications). EXPERIMENTAL DESIGN AND RESULTS: To identify the target gene(s) for 6p21 amplification, we constructed a detailed amplicon map at the region of genomic amplification with the aid of high-resolution contig array-based comparative genomic hybridization glass slides, consisting of contiguously ordered bacterial artificial chromosome/P1-derived artificial chromosome clones covering 3 Mb throughout the 6p21 amplification region. Alignment of the amplifications identified a minimally overlapping 800 kb segment containing 15 genes. Quantitative expression analysis of the genes from both patient samples and the SUDHL9 cell line revealed that CCND3 and BYSL (1.9 kb telomeric to the CCND3 gene locus) are the targets of 6p21 genomic gain/amplification. CONCLUSIONS: Although it is known that t(6;14)(p21;q32) induces aberrant overexpression of CCND3 in B-cell malignancies, we were able to show that CCND3, which encodes the cyclin D family member protein that controls the G1-S phase of cell cycle regulation, can also be a target of genomic gain/amplification. Overexpression of CCND3 through genomic amplification is likely to lead to aberrant cell cycle control, although the precise biological role of BYSL with respect to tumorigenesis remains to be determined. 相似文献
97.
Mami Hiraoka Shigeo Takashima Yoshiko Wakihara Yuji O. Kamatari Kaori Shimizu Ayaka Okada Yasuo Inoshima 《Viruses》2022,14(5)
Enzootic bovine leukosis (EBL) is a disease caused by bovine leukemia virus (BLV); only a small percentage of BLV-infected cattle develop EBL and present with B-cell lymphosarcoma. There is no vaccine against BLV, treatment for EBL, or method for predicting the possibility of EBL onset, thus making EBL control difficult. Herein, to explore biomarkers for EBL in milk, we examined the mRNA profiles of small extracellular vesicles (sEVs) in milk from four BLV-uninfected and four EBL cattle by microarray analysis. It was revealed that 14 mRNAs were encapsulated in significantly higher quantities, and these mRNAs were therefore selected as biomarker candidates. Primers for these mRNAs were designed, and nine primer sets were available for quantitative real-time PCR. Nine mRNAs were evaluated for their availability as biomarkers for EBL using sEVs from newly-collected milk of 7 uninfected and 10 EBL cattle. The quantities of eight mRNAs (TMEM156, SRGN, CXCL8, DEFB4A, FABP5, LAPTM5, LGALS1, and VIM) were significantly higher in milk sEVs of EBL cattle than in those of uninfected cattle. Therefore, our findings indicate that these eight mRNAs in milk sEVs can be used as potential EBL biomarkers with combination use, although single mRNA use is not enough. Consequently, cattle at risk of EBL onset can be identified by monitoring the fluctuation in quantities of these mRNAs in milk before they develop EBL. 相似文献
98.
99.